NorthView Acquisition Corp - Warrants (02/08/2027)
NVACW
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.34K
Close$
Share Statistics
| Market cap | $6,344.00 |
|---|---|
| Enterprise Value | $12.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-107.01 |
| Beta | 0.49 |
| Outstanding Shares | 57,676 |
Return
| Return on Equity | 142.73% |
|---|---|
| Return on Assets | -3715.66% |
| Return on Invested Capital | 120.58% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.06 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.39 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.06 |
| Debt to Equity | -0.49 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Profusa, Inc. Common Stock
2 employees
CEO: Ben Chung-Bin Hwang A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia